These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1670060)

  • 21. [Strongly increasing incidence of adenocarcinoma of the esophagus and gastric cardia].
    Walther C; Zilling T; Perfekt R; Möller T
    Lakartidningen; 2004 Jan; 101(3):180-3. PubMed ID: 14763086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of adenocarcinoma and squamous cell carcinoma of the esophagus with tobacco-related and other malignancies.
    Ahsan H; Neugut AI; Gammon MD
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):779-82. PubMed ID: 9332759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time trends and pathological profile of carcinoma lower oesophagus and gastro-oesophageal junction over the last 20 years--an experience from South India.
    Tony J; Kumar SK; Thomas V
    Trop Gastroenterol; 2007; 28(3):113-6. PubMed ID: 18383999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of surgical volume on hospital mortality and 5-year survival for carcinoma of the oesophagus and gastric cardia.
    Wenner J; Zilling T; Bladström A; Alvegård TA
    Anticancer Res; 2005; 25(1B):419-24. PubMed ID: 15816605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection.
    Cense HA; van Eijck CH; Tilanus HW
    Best Pract Res Clin Gastroenterol; 2006; 20(5):893-906. PubMed ID: 16997168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perinatal risk factors for cancer of the esophagus and gastric cardia: a nested case-control study.
    Akre O; Forssell L; Kaijser M; Norén-Nilsson I; Lagergren J; Nyrén O; Ekbom A
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):867-71. PubMed ID: 16702362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastric cancer: the correlation between the clinicopathological factors and patients' survival (I).
    Lazăr D; Tăban S; Dema A; Cornianu M; Goldiş A; Raţiu I; Sporea I
    Rom J Morphol Embryol; 2009; 50(1):41-50. PubMed ID: 19221644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report.
    Colin-Jones DG; Langman MJ; Lawson DH; Logan RF; Paterson KR; Vessey MP
    Gut; 1992 Sep; 33(9):1280-4. PubMed ID: 1358768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study.
    Colin-Jones DG; Langman MJ; Lawson DH; Vessey MP
    Br Med J (Clin Res Ed); 1982 Nov; 285(6351):1311-3. PubMed ID: 6812688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastric cancer in patients who have taken cimetidine.
    Taylor TV; Lee D; Howatson AG; Anderson J; MacLeod IB
    Lancet; 1979 Jun; 1(8128):1135-6. PubMed ID: 87674
    [No Abstract]   [Full Text] [Related]  

  • 31. Cimetidine use and gastric cancer.
    Schumacher MC; Jick SS; Jick H; Feld AD
    Epidemiology; 1990 May; 1(3):251-4. PubMed ID: 2081261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postmarketing surveillance of the safety of cimetidine: 12 month mortality report.
    Colin-Jones DG; Langman MJ; Lawson DH; Vessey MP
    Br Med J (Clin Res Ed); 1983 May; 286(6379):1713-6. PubMed ID: 6405946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users.
    Møller H; Nissen A; Mosbech J
    Gut; 1992 Sep; 33(9):1166-9. PubMed ID: 1358764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
    Brusselaers N; Lagergren J; Engstrand L
    Cancer Epidemiol; 2019 Oct; 62():101585. PubMed ID: 31445426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Esophageal cancer, gastric cancer and the use of pesticides in the southwestern of Turkey.
    Yildirim M; Kaya V; Yildiz M; Demirpence O; Gunduz S; Dilli UD
    Asian Pac J Cancer Prev; 2014; 15(6):2821-3. PubMed ID: 24761907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up.
    Colin-Jones DG; Langman MJ; Lawson DH; Vessey MP
    Br Med J (Clin Res Ed); 1985 Oct; 291(6502):1084-8. PubMed ID: 3931805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of cancer and acid suppressant treatment.
    Langman M; Logan R
    Gut; 2007 Jul; 56(7):1023. PubMed ID: 17566037
    [No Abstract]   [Full Text] [Related]  

  • 38. Gastric cancer in patients who have taken cimetidine.
    Reed PI; Cassell PG; Walters CL
    Lancet; 1979 Jun; 1(8128):1234-5. PubMed ID: 87691
    [No Abstract]   [Full Text] [Related]  

  • 39. Cancer occurrence in a cohort of patients treated with cimetidine.
    Møller H; Lindvig K; Klefter R; Mosbech J; Møller Jensen O
    Gut; 1989 Nov; 30(11):1558-62. PubMed ID: 2599442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial results of the oesophageal and gastric cancer registry from the Comunidad Valenciana.
    Escrig J; Mingol F; Martí R; Puche J; Trullenque R; Barreras JA; Asencio F; Aguiló J; Navarro JM; Alberich C; Salas D; Lacueva FJ;
    Cir Esp; 2017 Oct; 95(8):428-436. PubMed ID: 28807364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.